Research Alliance CORP Iv

Research Alliance Corporation IV announced the successful completion of its initial public offering and a concurrent private placement, raising a total of $77.75 million.

Research Alliance Corporation IV announced the pricing of its $75 million initial public offering and entered into material definitive agreements, including underwriting and indemnity agreements.

Research Alliance Holdings IV LLC reported changes in beneficial ownership of Research Alliance Corp IV common stock on July 14, 2026.

Matthew Hammond, Chief Executive Officer, a Director and 10% owner of Research Alliance Corp IV, received 275,000 shares of common stock on July 14, 2026.

Research Alliance Corporation IV has filed an S-1/A amendment, primarily to include an updated consent from its independent registered public accounting firm.

Research Alliance Holdings IV LLC and Matthew Hammond have jointly filed a Schedule 13D, reporting beneficial ownership of 17.0% of Research Alliance Corporation IV's Class A Ordinary Shares following the company's IPO and private placement.

Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have jointly filed a Schedule 13G, reporting beneficial ownership of 5.5% of Research Alliance Corporation IV's Class A Ordinary Shares.

Multiple Biotechnology Value Funds and Mark N. Lampert report a combined beneficial ownership of 6.4% in Research Alliance Corp IV Class A Ordinary Shares.

Commodore Capital LP, along with affiliated entities and individuals, has disclosed beneficial ownership of 5.5% of Research Alliance Corp IV's Class A Ordinary Shares.

Perceptive Advisors LLC, along with affiliated entities, has reported beneficial ownership of 700,000 Class A Ordinary Shares, representing 7.7% of the outstanding shares of Research Alliance Corporation IV.